Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.58 |
| ▸ | CTSK | P43235 | 8/20 | 0.58 |
| ▸ | CTSB | P07858 | 4/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519747 | 1.00 | CTSS (0.58) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL1519749 | 1.00 | CTSS (0.58) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL6292769 | 0.87 | CTSS (0.60) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL3922795 | 0.87 | CTSS (0.60) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2402235 | 0.87 | CTSS (0.60) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2329795 | 0.86 | CTSS (0.65) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2329798 | 0.86 | CTSS (0.65) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL3060826 | 0.86 | CTSS (0.63) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL21583948 | 0.86 | CTSS (0.63) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL3060829 | 0.86 | CTSS (0.63) | CTSSCTSKCTSBCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| EP-3037418-B1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2019-10-02 | — | — | EP | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | CTSS 3106/4885CTSK 2170/4885CTSB 1409/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | CTSS 3180/4885CTSK 2399/4885CTSB 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.